Pancreatic Adenosquamous Carcinoma clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
Sorry, not accepting new patients
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.
Los Angeles, California and other locations
Last updated: